Implantable cardioverter-defibrillator (ICD) therapy reduces mortality in patients with
chronic heart failure and reduced left ventricular ejection fraction (LVEF) <36%.
Nevertheless, patient selection for ICD therapy based on LVEF and NYHA functional class alone
seems to have a low specificity and sensitivity: In 100 patients treated, the SCD-HeFT study
prevented 7 deaths in 5 years. Therefore 93 patients have a risk of adverse effects, such as
operation risk, infection, pneumothorax, lead dislocation, and inadequate icd therapy. On the
other hand, patients with advanced or end stage heart failure might rather die off
progressive heart failure death and thus not benefit from ICD therapy.
It therefore seems appropriate and necessary to improve the individualized risk
stratification in these patients. The aim of this study is to evaluate multiple cardiac
biomarkers in a model predicting ventricular arrhythmias in patients on ICD therapy.